Pliant Therapeutics PLRX Income Statement (2019-2026)

NASDAQ PLRX
$1.12 -0.05 (-4.27%)
As of: Aug 20, 2026 · 3:59 PM EDT
Income Statement Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
35.98M36.08M36.16M36.18M48.75M48.94M58.98M59.22M59.89M59.92M60.32M60.43M60.85M60.86M61.39M61.39M61.45M61.45M61.91M61.92M
Revenue & cost
Revenue (Quarter)
1.61M2.00M1.25M4.99M1.48M1.97M1.33M0.25M
Operating items
Research & Development (Quarter)
21.05M18.75M20.88M26.34M24.61M25.11M29.27M33.00M32.34M33.18M37.15M45.62M47.75M38.79M43.44M32.20M17.94M15.59M13.58M16.73M
Selling, General & Administrative (Quarter)
7.67M7.85M8.58M8.30M8.82M14.25M14.15M14.57M15.35M13.85M15.25M15.02M14.26M14.53M15.50M13.39M10.33M7.99M8.19M7.13M
Operating Expenses (Quarter)
28.72M26.60M29.46M34.63M33.43M39.37M43.43M47.58M47.69M47.04M52.39M60.64M62.01M53.32M58.94M45.59M28.27M23.58M21.77M23.86M
Operating Income (Quarter)
-27.11M-24.60M-28.21M-29.64M-31.95M-37.40M-42.09M-47.33M-47.69M-47.04M-52.39M-60.64M-62.01M-53.32M-58.94M-45.59M-28.27M-23.58M-21.77M-23.86M
EBIT (Quarter)
-27.11M-24.60M-28.21M-29.64M-31.95M-37.40M-42.09M-47.33M-47.69M-47.04M-52.39M-60.64M-62.01M-53.32M-58.94M-45.59M-28.27M-23.58M-21.77M-23.86M
Non-operating items
Interest & Investment Income (Quarter)
0.07M-0.16M-0.75M-0.31M-1.20M0.50M0.63M-0.91M0.33M-15.52M-0.83M-0.13M1.47M-0.53M-0.16M-0.16M0.04M11.70M1.73M1.49M
Other Non Operating Income (Quarter)
Net income details
EBT (Quarter)
-27.14M-23.46M-29.56M-30.15M-33.44M-35.80M-41.78M-48.56M-47.67M-62.88M-53.73M-61.63M-61.43M-55.02M-59.90M-86.29M-29.05M-15.01M-57.31M-22.37M
Profit After Tax (Quarter)
-0.01M-24.70M-28.10M-29.55M-31.81M0.50M-37.55M-41.19M0.33M-38.81M-46.95M-55.85M1.47M-50.26M-0.16M-43.30M0.04M-149.39M-20.37M-22.43M
Income from Continuing Operations (Quarter)
-27.14M-23.46M-29.56M-30.15M-33.44M-35.80M-41.78M-48.56M-47.67M-62.88M-53.73M-61.63M-61.43M-55.02M-59.90M-86.29M-29.05M-15.01M-57.31M-22.37M
Consolidated Net Income (Quarter)
-27.14M-23.46M-29.56M-30.15M-33.44M-35.80M-41.78M-48.56M-47.67M-62.88M-53.73M-61.63M-61.43M-55.02M-59.90M-86.29M-29.05M-15.01M-57.31M-22.37M
Income towards Parent Company (Quarter)
-27.14M-23.46M-29.56M-30.15M-33.44M-35.80M-41.78M-48.56M-47.67M-62.88M-53.73M-61.63M-61.43M-55.02M-59.90M-86.29M-29.05M-15.01M-57.31M-22.37M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-62.88M-53.73M-61.63M-61.43M-55.02M-59.90M-86.29M-29.05M-15.01M-57.31M-22.37M
Additional items
EPS (Basic) (Quarter)
-0.75-0.68-0.78-0.82-0.65-0.83-0.67-0.70-0.70-1.07-0.89-1.02-1.01-0.91-0.98-1.41-0.47-0.24-0.93-0.36
EPS (Diluted) (Quarter)
-0.75-0.68-0.78-0.82-0.65-0.83-0.67-0.70-0.70-1.07-0.89-1.02-1.01-0.91-0.98-1.41-0.47-0.24-0.93-0.36
Shares Outstanding (Quarter)
35.91M35.85M36.12M36.17M46.80M42.02M56.06M59.17M59.69M58.72M60.18M60.38M60.73M60.54M61.22M61.39M61.41M61.37M61.80M61.92M
Shares Outstanding (Diluted) (Quarter)
35.91M35.85M36.12M36.17M46.80M42.02M56.06M59.17M59.69M58.72M60.18M60.38M60.73M60.54M61.22M61.39M61.41M61.37M61.80M61.92M
EBITDA (Quarter)
-27.11M-24.60M-28.21M-29.64M-31.95M-37.40M-42.09M-47.33M-47.69M-47.04M-52.39M-60.64M-62.01M-53.32M-58.94M-45.59M-28.27M-23.58M-21.77M-23.86M
Interest Expenses (Quarter)
0.10M-1.30M0.60M0.20M0.30M-1.10M0.31M0.32M0.32M0.32M0.50M0.87M0.88M1.17M0.80M40.53M0.81M3.14M37.27M